Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Dare Bioscience (DARE) EBIT Margin (2016 - 2025)

Dare Bioscience (DARE) has disclosed EBIT Margin for 6 consecutive years, with 162340.76% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT Margin fell 15111208.0% year-over-year to 162340.76%, compared with a TTM value of 30578.09% through Sep 2025, up 3181312.0%, and an annual FY2024 reading of 239692.2%, down 23859031.0% over the prior year.
  • EBIT Margin was 162340.76% for Q3 2025 at Dare Bioscience, down from 18079.54% in the prior quarter.
  • Across five years, EBIT Margin topped out at 18079.54% in Q2 2025 and bottomed at 162340.76% in Q3 2025.
  • Average EBIT Margin over 4 years is 26370.57%, with a median of 6034.16% recorded in 2023.
  • Peak annual rise in EBIT Margin hit 5087866bps in 2025, while the deepest fall reached -15111208bps in 2025.
  • Year by year, EBIT Margin stood at 3.84% in 2022, then plummeted by -7543bps to 286.05% in 2023, then soared by 3060bps to 8465.75% in 2024, then crashed by -2018bps to 162340.76% in 2025.
  • Business Quant data shows EBIT Margin for DARE at 162340.76% in Q3 2025, 18079.54% in Q2 2025, and 18016.75% in Q1 2025.